Inadequate safety reporting in the publications of randomised clinical trials in irritablebowel syndrome: drug versus probiotic interventions

Inadequate safety reporting in the publications of randomised clinical trials in irritablebowel syndrome: drug versus probiotic interventions

A.M. van der Geest1*, I. Schukking1, R.J.M. Brummer2, H. Pieterse3, M. van den Nieuwboer4, L.H.M. van deBurgwal1 and O.F.A. Larsen

Vrije Universiteit Amsterdam, Athena Institute, De Boelelaan 1085, 1081 HV Amsterdam, the Netherlands; 2Nutrition-Gut-Brain Interactions Research Centre, School of Medical Sciences, Faculty of Medical and Health Sciences, Örebro University,Fakultetsgatan 1, 70182 Örebro, Sweden; 3University of Ghent, Heymans Institute of Pharmacology, C. Heymanslaan 10,9000 Ghent, Belgium; 4Stichting Darmgezondheid, Oversteek 35, 6717 ZS Ede, the Netherlands;
(PDF) Inadequate safety reporting in the publications of randomised clinical trials in irritable bowel syndrome: drug versus probiotic interventions. Available from: https://www.researchgate.net/publication/362078004_Inadequate_safety_reporting_in_the_publications_of_randomised_clinical_trials_in_irritable_bowel_syndrome_drug_versus_probiotic_interventions[accessed Jan 31 2023].